ADVERTISEMENT
Advertise

Content

List volumes - List articles in this issue

Progress in Heritable Skin Diseases: Translational Implications of Mutation Analysis and Prospects of Molecular Therapies

doi: 10.2340/00015555-0648

Abstract:

Epidermolysis bullosa, a group of blistering disorders, serves as the paradigm of the tremendous progress made in understanding the molecular genetics of heritable skin diseases. Mutations in 10 distinct genes have been disclosed in the classic forms of epidermolysis bullosa, and the level of expression of the mutated genes within the cutaneous basement membrane zone, the types and combinations of mutations and their consequences at the mRNA and protein levels, when placed in the context of the individual's genetic background and exposure to environmental trauma, all determine the subtype and the phenotypic severity in each case. The translational implications of mutation analysis include improved diagnosis and subclassification, refined genetic counseling of families at risk, and development of DNA-based pre natal and preimplantation genetic diagnosis. The prospects of molecular therapies for epidermolysis bullosa include further development of strategies for gene therapy, protein replacement therapy and cell-based therapies, including stem cell therapy and bone marrow transfer. Collectively, advances in the molecular genetics of heritable skin diseases clearly emphasize the value of basic research for improved diagnostics and patient care for genetic skin diseases.

Authors:

Jouni Uitto

References

  1. Pulkkinen L, Ringpfeil F, Uitto J. Progress in heritable skin diseases: molecular bases and clinical implications. J Am Acad Dermatol 2002; 47: 91–104. [CrossRef]
  2. Uitto J, Christiano AM. Molecular genetics of the cutaneous basement membrane zone. Perspectives on epidermolysis bullosa and other blistering skin diseases. J Clin Invest 1992; 90: 687–692. [CrossRef]
  3. Li Q, Jiang Q, Pfendner E, Váradi A, Uitto J. Pseudoxanthoma elasticum: clinical phenotypes, molecular genetics and putative pathomechanisms. Exp Derm 2009; 18: 1–11. [CrossRef]
  4. Fine JD, Eady RAJ, Bauer EA, Bauer J, Bruckner-Tuderman L, Heagerty A, et al. The classification of inherited epidermolysis bullosa (EB): report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Derm 2008; 58: 931–950. [CrossRef]
  5. Uitto J, Richard G. Progress in epidermolysis bullosa: from eponyms to molecular genetic classification. Clin Dermatol 2005; 23: 33–40. [CrossRef]
  6. Pulkkinen L, Uitto, J. Hemidesmosomal variants of epidermolysis bullosa. Mutations in the α6β4 integrin and the 180-kD bullous pemphigoid antigen/type XVII collagen genes. Exp Derm 1998; 7: 46–64. [α6β4 integrin and the 180-kD bullous pemphigoid antigen/type XVII collagen g&firsta=Pulkkinen L&volume=&year=enes&key=3014-1">CrossRef]
  7. Varki R, Sadowski S, Pfendner E, Uitto J. Epidermolysis bullosa. I. molecular genetics of the junctional and hemidesmosomal variants. J Med Genet 2006; 43: 641–652. [CrossRef]
  8. Varki R, Sadowski S, Uitto J, Pfendner E. Epidermolysis bullosa. II. Type VII collagen mutations and phenotype/genotype correlations in the dystrophic subtypes. J Med Genet 2007; 44: 181–192. [CrossRef]
  9. Jonkman MF, Pasmooij AM, Pasmans SG, van den Berg MP, Ter Horst HJ Timmer A, et al. Loss of desmoplakin tail causes lethal acantholytic epidermolysis bullosa. Am J Hum Genet 2005; 77: 653–660. [CrossRef]
  10. McGrath JA, McMillan JR, Shemanko CS, Runswick SK, Leigh IM, Lane EB, et al. Mutations in the plakophilin 1 gene result in ectodermal dysplasia/skin fragility syndrome. Nat Genet 1997; 17: 240–244. [CrossRef]
  11. Hamada T, South AP, Mitsuhashi Y, Kinebuchi T, Bleck O, Ashton GH, et al. Genotype-phenotype correlation in skin fragility-ectodermal dysplasia syndrome resulting from mutations in plakophilin 1. Exp Dermatol 2002; 11: 107–114. [CrossRef]
  12. Sprecher E, Molho-Pessach V, Ingber A, Sagi E, Indelman M, Bergman R. Homozygous splice site mutations in PKP1 result in loss of epidermal plakophilin 1 expression and underlie ectodermal dysplasia/skin fragility syndrome in two consanguineous families. J Invest Dermatol 2004; 122: 547–651. [CrossRef]
  13. Ashton GH, McLean WH, South AP, Oyama N, Smith FJ, Al-Suwaid R, et al. Recurrent mutations in kindlin-1, a novel keratinocyte focal contact protein, in the autosomal recessive skin fragility and photosensitivity disorder, Kindler syndrome. J Invest Dermatol 2004; 122: 78–83. [CrossRef]
  14. Arita K, Wessagowit V, Inamadar AC, Palit A, Fassihi H, Lai-Cheong JE, et al. Unusual molecular findings in Kindler syndrome. Br J Dermatol 2007; 157: 1252–1256. [CrossRef]
  15. Gu LH, Kim SC, Ichiki Y, Park J, Nagai M, Kitajima Y. A usual frameshift and delayed termination codon mutation in keratin 5 causes a novel type of epidermolysis bullosa simplex with migratory circinate erythema. J Invest Dermatol 2003; 121: 482–485. [CrossRef]
  16. Hashimoto I, Kon A, Tamai K, Uitto J. Diagnostic dilemma of “sporadic” cases of dystrophic epidermolysis bullosa: a new dominant or mitis recessive mutation? Exp Derm 1999; 8: 140–142. [CrossRef]
  17. Pfendner E, Nakano A, Pulkkinen L, Christiano AM, Uitto J. Prenatal diagnosis for epidermolysis bullosa: a study of 144 consecutive pregnancies at risk. Prenat Diagn 2003; 23: 447–456. [CrossRef]
  18. Cserhalmi-Friedman PB, Tang Y, Adler A, Krey L, Grifo JA, Christiano AM. Preimplantation genetic diagnosis in two families at risk for recurrence of Herlitz junctional epidermolysis bullosa. Exp Dermatol 2000; 9: 290–297. [CrossRef]
  19. Fassihi H, Grace J, Lashwood A, Whittock NV, Braude PR, Pickering SJ, et al. Preimplantation genetic diagnosis of skin fragility-ectodermal dysplasia syndrome. Br J Dermatol 2006; 154: 546–550. [CrossRef]
  20. Macek M Sr., Bianchi D, Cukkle H, editors. Early prenatal diagnosis, fetal cells and DNA in the mother. Prague: Karolinum Press, 2002. [CrossRef]
  21. Uitto J, Pfendner E, Jackson LC. Probing the fetal genome: progress towards non-invasive prenatal diagnosis. Trends Mol Med 2003; 9: 339–343. [CrossRef]
  22. Lo YM. Non-invasive prenatal diagnosis using fetal cells in maternal blood. J Clin Pathol 1994; 47: 1060–1065. [CrossRef]
  23. Chiu RW, Lo YM. Non-invasive prenatal diagnosis by analysis of fetal DNA in maternal plasma. Methods Mol Biol 2006; 336: 101–109. [CrossRef]
  24. Krabchi K, Gros-Louis F, Yan J, Bronsard M, Massé J, Forest JC, et al. Quantification of all fetal nucleated cells in maternal blood between the 18th and 22nd weeks of pregnancy using molecular cytogenetic techniques. Clin Genet 2001; 60: 145–150. [CrossRef]
  25. Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S, DeMaria MA. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc Natl Acad Sci USA 1996; 93: 705–708. [CrossRef]
  26. Kaiser J. An earlier look at baby’s genes. Science 2005; 309: 1476–1478. [CrossRef]
  27. Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999; 64: 218–224. [CrossRef]
  28. Tsui NB, Lo YM. A microarray approach for systematic identification of placental-derived RNA markers in maternal plasma. Methods Mol Biol 2008; 444: 275–289. [CrossRef]
  29. Avent ND. RHD genotyping from maternal plasma: guidelines and technical challenges. Methods Mol Biol 2008; 444: 185–201. [CrossRef]
  30. Uitto J, Pulkkinen L. The genodermatoses: candidate diseases for gene therapy. Hum Gene Ther 2000; 11: 2267–2275. [CrossRef]
  31. Jiang Q-J, Uitto J. Animal models of epidermolysis bullosa – targets for gene therapy. J Invest Dermatol 2005; 124: xi–xiii. [CrossRef]
  32. Mavilio F, Pellegrini G, Ferrari S, Di Nunzio F, Di Iorio E, Recchia A, et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med 2006; 12: 1397–1402. [CrossRef]
  33. Woodley DT, Keene DR, Atha T, Huang Y, Lipman K, Li W, et al. Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med 2004; 10: 693–695. [CrossRef]
  34. Remington J, Wang X, Hou Y, Zhou H, Burnett J, Muirhead T, et al. Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Mol Ther 2009; 17: 26–33. [CrossRef]
  35. Igoucheva O, Kelly A, Uitto J, Alexeev V. Protein therapeutics for junctional epidermolysis bullosa: incorporation of recombinant β3 chain into laminin 332 in β3–/– keratinocytes in vitro. J Invest Dermatol 2008; 128: 1476–1486. [CrossRef]
  36. Goto M, Sawamura D, Ito K, Abe M, Nishie W, Sakai K, et al. Fibroblasts show more potential as target cells than keratinocytes in COL7A1 gene therapy of dystrophic epidermolysis bullosa. J Invest Dermatol 2006; 126: 766–772. [CrossRef]
  37. Woodley DT, Remington J, Huang Y, Hou Y, Li W, Keene DR, et al. Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. Mol Ther 2007; 15: 628–635. [CrossRef]
  38. Wong T, Gammon L, Liu L, Mellerio JE, Dopping-Hepenstal PJ, Pacy J, et al. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2008; 128: 2179–2189. [CrossRef]
  39. Uitto J. Epidermolysis bullosa: prospects for cell-based therapies. J Invest Dermatol 2008; 128: 2140–2142. [CrossRef]
  40. Chino T, Tamai K, Yamazaki T, Otsuru S, Kikuchi Y, Nimura K, et al. Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance. Am J Pathol 2008; 173: 803–814. [CrossRef]
  41. Tolar J, Ishida-Yamamoto A, Riddle M, McElmurry RT, Osborn M, Xia L, et al. Correction of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood 2009; 113: 1167–1174. [CrossRef]
  42. Heinonen S, Männikkö M, Klement JF, Whitaker-Menezes D, Murphy GF, Uitto J. Targeted inactivation of the type VII collagen gene (Col7a1) in mice results in severe blistering phenotype: a model for recessive dystrophic epidermolysis bullosa. J Cell Sci 1999; 112: 3641–3648. [CrossRef]

Share with your friends





Actions


Abstract

Full text

PDF

Supplementary


There is no supplementary for this article.

Print information


Volume 89, Issue 3

DOI: 10.2340/00015555-0648

Pages: 228-235

View at PubMed